Stifel Nicolaus analyst Eric Le Berrigaud has maintained their bullish stance on SNYNF stock, giving a Buy rating on April 17.
Eric Le Berrigaud has given his Buy rating due to a combination of factors including Sanofi’s strong financial performance in the first quarter, which exceeded expectations by €250 million at the top-line level. This was driven by successful new product launches such as Beyfortus and Altuviiio, as well as the continued strong performance of their insulin portfolio in the US market. Additionally, the company achieved a significant improvement in gross margin by 250 basis points, reflecting a favorable product mix and effective cost management.
Furthermore, Sanofi’s core operating margin showed a notable increase, and the company maintained a strong dividend yield, which is projected to rise over the next few years. Despite a temporary increase in the tax rate, the overall financial outlook remains positive, offering potential upside to the full-year guidance. These factors, combined with promising developments in their R&D pipeline, underpin the Buy rating from Eric Le Berrigaud.
Le Berrigaud covers the Healthcare sector, focusing on stocks such as Sanofi, Innate Pharma SA, and Sandoz Group Ltd. According to TipRanks, Le Berrigaud has an average return of 5.5% and a 52.38% success rate on recommended stocks.
In another report released on April 17, UBS also maintained a Buy rating on the stock with a €120.00 price target.